OUR APPROACH
Inspired by Nvidia CEO Jensen Huang’s “Huang’s Law,” which predicts that the AI reasoning of AI will increase 1,000 times every decade, our investment strategy at APM Vision Capital is focused on using AI to accelerate the advancement of preventive medicine. By investing in AI-driven solutions, we believe that AI will break down barriers to biomedical research, reduce costs, time and human resource requirements, accelerate the research and development and popularization of medicine and drugs tenfold or even a hundredfold, thereby saving more lives. Simultaneously bringing new possibilities for predictive and preventive healthcare.
INVESTMENT STRATEGY
01.
Focus on AI-Enabled Biomedical Innovations
We prioritize investments in companies that utilize AI to drive faster and more precise advancements in preventive medicine, enabling earlier diagnostics, risk assessment, and proactive health management.
02.
Support Data-Driven Preventive Health Solutions
Investing in technologies that harness big data to transform preventive healthcare—from population health management to personalized predictive analytics—bringing data-driven precision to decision-making.
03.
Invest in High-Performance AI-Medtech Infrastructure
As AI computation advances, we back innovations in high-efficiency AI hardware, computing platforms, and robotics, building the technological foundation needed to accelerate large-scale data analysis and medical applications.
04.
Transforming Time and Cost-Intensive Research
We seek to revolutionize traditional, resource-heavy biomedical production services by introducing AI into clinical trials, drug discovery, and disease modeling, and medicine productions. Driving automation and efficiency.
05.
Expand Market Reach of Preventive Medicine Solutions
Our strategy emphasizes the commercialization and scaling of impactful preventive health technologies to ensure broad access, improving lives globally.
OUR PORTFOLIO
Our diverse portfolio embodies our vision for a future where advanced healthcare and longevity solutions are accessible worldwide. We invest in companies at the forefront of regenerative medicine, artificial intelligence (AI) in healthcare, and MedTech innovations that redefine preventive medicine and enhance quality of life. Our portfolio spans a range of specialized sectors, including stem cell therapy, AI-driven diagnostics, exosome-based treatments, and advanced robotics for medical applications.
Our investments strategically target high-growth companies in Asia and globally, focusing on transformative solutions that address major health challenges and extend healthy lifespans. Each company in our portfolio is selected for its commitment to pushing the boundaries of science and technology to improve patient outcomes, prevent disease, and promote wellness. By providing resources and leveraging our extensive network of medical experts and healthcare institutions, we empower these companies to innovate, scale, and bring their life-changing solutions to broader markets, advancing the future of preventive healthcare.
Current Pipelines
